Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma

Published

on

UniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by Replimune and Capricor.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

AbbVie shares pressured as Q2 I&I beat falls below investor expectations

Published

on

AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.

Continue Reading

Uncategorized

Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%

Published

on

Novo Nordisk’s IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.

Continue Reading

Uncategorized

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Read More

Published

on

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Read More

Continue Reading
Advertisement

Trending